San Francisco, California, April 23, 2018: The market for refractory angina treatment is driven by the rising awareness of the risk factors and medical therapies and devices for the management of the debilitating cardiovascular condition. The rising worldwide prevalence of refractory angina, especially in aging population, and associated morbidity in patients has led clinicians increasingly focus on this condition. A new report by TMR Research, titled, “Refractory Angina Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017–2025”, presents a critical assessment of such trends and factors and evaluates their impact on the emerging growth trajectory over the forecast period of 2017–2025.
The growing availability of treatments for managing the symptoms for managing chronic chest pain is boosting the market. Coupled with this, the constantly expanding experimental and palliative options for disease treatment is a notable factor accentuating the growth of the market. The increased spending on healthcare resources for the management of the persistent chest discomfort is also favoring the growth of the market.
Get Sample Copy of this Report @
The medical fraternity is spending substantial sums in research and development of new drug varieties for refractory angina bodes well for the market. In developed markets, there has been rapid stride in understanding the etiology and epidemiology of the disease and develop more efficacious treatment modalities. In this regard, cellular therapies are garnering wide attention among companies engaged in developing novel treatments. A number of recent clinical trials has provided a striking thrust to the effectiveness of cellular therapies. Furthermore, gene-based therapies are appearing as promising in the management of refractory angina.
Some of the popular treatment methods are invasive and noninvasive non-pharmacological therapies and pharmacological therapies.
Prominent players operating in the refractory angina market include Cryopraxis, Vasomedical, Inc, Saneron CCEL Therapeutics, Inc., Neovasc Inc., and Ark Therapeutics Group plc.